Acute lower respiratory tract disease (aLRTD), including acute lower respiratory tract infection (aLRTI) such as pneumonia and non-pneumonic LRTI (NP-LRTI), is a leading cause of hospitalisation and death, especially in older adults and those with comorbidities. Non-pulmonary complications and subsequent functional decline after aLRTI have been recognised, but the pathogen-specific burden of these extra-pulmonary outcomes has been incompletely described. The AvonCAP group conducted a prospective cohort study to quantify acute renal, hepatic, thromboembolic and functional complications, and mortality, following hospitalisation with aLRTD, and to compare outcomes by clinical phenotype and identified pathogens.
This was a cohort study of adults (>18 years) admitted with aLRTD to two hospitals in Bristol, UK between 01 August 2022 and 31 July 2024. Admissions were classified at the time of care as pneumonia, NP-LRTI or no diagnosis of aLRTI. Pathogens were identified using standard-of-care and research microbiology. Outcomes assessed descriptively included acute kidney injury (AKI), acute liver dysfunction, venous thromboembolism (VTE; DVT and PE), in-hospital falls, reduced mobility at discharge, increased care requirements at discharge, and mortality at 30 days and 1 year.
Of 21,456 aLRTD hospitalisations included in the analysis, 19,152 admissions underwent microbiological or virological testing. Among those tested, 8,503 admissions (44.4%) yielded at least one positive result, producing 9,204 pathogen detections. Co-infections were identified in 1,194 admissions (6.2% of tested admissions). Across the cohort, SARS-CoV-2 was the most frequently detected pathogen overall. Influenza was the second most common pathogen in both pneumonia and NP-LRTI subgroups.
Pneumonia presented with greater clinical severity compared with NP-LRTI and admissions without aLRTI. Median length of stay was longest for pneumonia (6 days) and shorter for NP-LRTI and no aLRTI (each 4 days). Intensive care unit admission rates were 3.4% for pneumonia, compared with 0.7% for NP-LRTI and 0.5% for admissions without aLRTI.
Across the included aLRTD hospitalisations, non-pulmonary complications were common. Overall rates reported were:
These events were more frequent in the pneumonia subgroup than in NP-LRTI or admissions without aLRTI, consistent with the greater severity observed in pneumonia.
Functional decline during hospitalisation and altered care needs at discharge were notable. Overall 1.8% of admissions had an in-hospital fall. Reduced mobility at discharge was recorded in 11.5% of admissions, and 16.6% of patients required increased care on discharge compared with their pre-admission baseline. These functional outcomes indicate a substantial burden of post-infection disability and dependence arising from aLRTD admissions.
Mortality was highest among patients with pneumonia. The study reported 30-day mortality of 14.0% and 1-year mortality of 32.0% for the pneumonia subgroup. Mortality rates were lower in NP-LRTI and admissions without evidence of aLRTI, mirroring differences in clinical severity and complication rates.
Analyses by pathogen indicated heterogeneity in clinical course and outcomes. Admissions with SARS-CoV-2 and Streptococcus pneumoniae detections were associated with longer hospital stays, higher rates of complications (including AKI, hepatic dysfunction and VTE) and higher mortality. In contrast, admissions with influenza and Haemophilus influenzae detections tended to have shorter lengths of stay and lower complication and mortality rates. The study provides descriptive pathogen-specific comparisons but did not report adjusted effect estimates in the abstract.
The authors conclude that non-cardiovascular complications and functional decline after aLRTI are common, particularly in pneumonic disease and illnesses due to SARS-CoV-2 or pneumococcus. They suggest these findings support routine surveillance for renal, hepatic and thromboembolic events in patients hospitalised with aLRTD, and emphasise the role of early mobilisation and rehabilitation to mitigate functional decline. The authors also propose that multi-system outcomes should be considered when evaluating the public health and economic value of vaccines and therapies for respiratory pathogens.
The study received ethical approval from the East of England - Essex Research Ethics Committee (REC ref: 20/EE/0157). The authors state that relevant participant consent was obtained. Funding information declared includes support from Pfizer; several authors are employees of Pfizer and some report potential competing interests. The study notes that the individual participant data are sensitive and cannot be made publicly available without breaching patient confidentiality; therefore, the data are not available to other researchers from the report.